Biotech | August 12, 2021
Global cell expansion market poised for huge growth
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
The goal for the project is the identification and optimization of anti-viral compounds.
The company has already embarked upon significant expansion in Turkey
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
Subscribe To Our Newsletter & Stay Updated
